drugset
drugset / Trial / NCT04314895

Trial of NanoPac Intratumoral Injection in Lung Cancer

NCT04314895 ↗

Phase 2 Completed 18 enrolled NanOlogy, LLC US Biotest, Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

This study evaluates the use of NanoPac injected directly into tumors in the lung of people with lung cancer.

Timeline

Start
2021-04-14
Primary completion
2023-09-26
Completion
2023-09-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Paclitaxel Small molecule 15 mg/ml Other

Indications

non-small cell lung carcinoma small cell lung carcinoma